Omnicell Inc Q4 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So firstly, so it's great to know that you guys have 145 sole source agreements with these top 300 health systems. I'm just curious if you can kind of talk about what details are included in these agreements? And then from these agreements, do you kind of have a sense of what product offerings these hospital systems are interested in purchasing? And also, I'm wondering like what percentage of these customers have expressed an interest in buying things like central pharmacies, a sensing system, like IV compounding system or even like a Omnicell software platform that you guys have?

Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Okay. That's very helpful. And then a follow-up question. You guys talked about you're targeting 50% CAGR for the SaaS subscription revenue and the tech-enabled services. I'm just wondering like, Scott, you have mentioned there are so many moving pieces here. Can you kind of name a few products or service that you expect to have the highest growth in the near term, maybe like 12 to 18 months? And then I'm also wondering, is that 50% growth organic? Or have you kind of baked in the assumption of acquisitions?